Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 206

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 206
---
 internal control over financial reporting. 

138

Item 9B. Other Information.

Director and Officer Trading Arrangements:

Rule 10b5-1 Trading PlansFrom time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2024, certain of our officers adopted such trading arrangements as noted below: 

      Trading Arrangement

      Name and Title
       
      Action
       
      Date
       
      Rule 10b5-1*
       
      Non-Rule 10b5-1**
       
      Total Shares Authorized to be Sold***

      Expiration Date

      Todd HarrisPresident, Chief Executive Officer and Director
       
       Adoption
       
      11/4/2024
       
      X

      315,000

      12/31/2026

      Daniel BensenChief Operating Officer
       
       Adoption
       
      11/5/2024
       
      X

      350,000

      2/26/2027

      Alan FuhrmanChief Financial Officer
       
       Adoption
       
      11/5/2024
       
      X

      80,000

      7/31/2026
     
     * Intended to satisfy the affirmative defense of Rule 10b5-1(c) ** Not intended to satisfy the affirmative defense of Rule 10b5-1(c) *** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of  shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards. 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

Information required by this item and not set forth below will be contained in our definitive proxy statement to be filed with the SEC in connection with our 2025 Annual Meeting of Stockholders (the Definitive Proxy Statement), which is expected to be filed not later than 120 days after the